Benitec Biopharma Inc. Common Stock (BNTC)

About BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

19

Website

benitec.com/

Fundamentals

1-day range

$11.71$12.76

Market cap

$451.07M

P/E (trailing)

—

P/E (forward)

-1.32

EPS (trailing)

$-1.11

Dividend yield

—

Beta

0.25

Avg. volume

141.1K

Dividend pay date

November 18, 2019

Forecasts

6 analyst ratings

Benitec Biopharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $451.07MP/E —
  $9.85$16.76
• RZLT

  Rezolute Inc. Common Stock (NV)

  $4.62

  ▼ 7.23%
  Market cap $452.57MP/E —
  $1.07$11.46
• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $449.19MP/E —
  $7.73$11.8
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $436.31MP/E —
  $2.72$6.42
• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $482.18MP/E 15.71
  $1.62$23.57
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $487.98MP/E —
  $3.86$9.12
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $413.30MP/E 18.65
  $4.3$9.51

P/E shows — for peers not currently carrying a live signal of their own.

• Friedman David Matthew · May 26, 2026 · Grant

  35.0K

Institutional Ownership

March 31, 2026

Total shares held

32.09M

Total value held

$341.84M

Institutional holders

84